Pharma’s Pricing Tricks: Patients Lose, Profits Soar
The Harsh Reality Behind Pharma’s Latest Pricing Tricks and Policy Evasions Big Pharma’s Desperate Dance: How Drugmakers Manipulate Regulations to
Read More
Super Metals: Hype in Luxury, Danger in Defense
The Dangerous Delusions of a Startup’s “Super Metals” and What It Means for Tech’s Future Warning: This Startup’s “Super Metals”
Read MoreBlackRock’s Bitcoin ETF: Investor Trap or Golden Opportunity?
BlackRock’s Bitcoin ETF: A Wolf in Institutional Clothing Designed to Bleed Investors Dry BlackRock dangles a new Bitcoin ETF as
Read MoreAmerica’s Congenital Syphilis Crisis: Unchecked Failures
Congenital Syphilis Is Making a Comeback — And America’s Healthcare System Is Laughing at Its Own Failure Congenital syphilis cases
Read MoreSpaceX’s $60B AI Bet: Ambition, Hype, and Reality Clash
SpaceX’s $60 Billion AI Folly: When Ambition Meets Hubris and Wall Street Mania SpaceX’s $60 Billion AI Folly: When Ambition
Read MoreBitcoin Buying Frenzy: A Dangerous Prelude to Collapse
Bitcoin’s False Dawn: Why the Latest Buying Frenzy Is a Prelude to Catastrophe Bitcoin buyers are piling into the market
Read MoreThreads’ 500M Users: Growth or Digital Illusion?
Meta’s Threads Hits 500 Million Users—But Prepare for More Smoke and Mirrors, Not Real Change Key Takeaways Meta’s Threads boasts
Read MoreBitcoin’s Fake Rally: Crypto Market’s Rotten Core Exposed
Bitcoin’s Fake Rally Exposes the Rotten Core of Crypto Markets as Altcoins Pretend to Keep Up Bitcoin spikes after a
Read MoreBitcoin’s Temporary Surge Masks Market Instability
Bitcoin’s False Hope Rally Exposes the Market’s Fragility and Hype-Fueled Delusions Key Takeaways Bitcoin’s recent rebound to $64,000 is nothing
Read MoreBenchmark’s $2B Fund: Death of VC Discipline
Benchmark’s $2 Billion Growth Fund: The Death Knell of True Venture Capital Discipline Key Takeaways Benchmark shatters its two-decade-long disciplined
Read More